ID

24654

Descrizione

Study ID: 101468/228 Clinical Study ID: 101468/228 Study Title:A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00363727 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Dyskinesias; Parkinson Disease; Parkinson's Disease Study part: Inclusion/exclusion.

Keywords

versioni (2)
  1. 11/08/17 11/08/17 -
  2. 07/09/17 07/09/17 -
Titolare del copyright

GlaxoSmithKline

Caricato su

11 agosto 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Inclusion/exclusion GSK study Dyskinesia in Parkinson's disease NCT00363727

Inglese

Inclusion/exclusion GSK study Dyskinesia in Parkinson's disease NCT00363727

1 moduli  
General information
Descrizione

General information

Protocol identifier
Descrizione

Protocol identifier

Tipo di dati

text

Subject Identifier
Descrizione

Subject Identifier

Tipo di dati

text

Alias
UMLS CUI [1]
C2348585
Visit Description
Descrizione

Visit Description

Tipo di dati

text

Inclusion and exclusion criteria
Descrizione

Inclusion and exclusion criteria

Monitor data validation check
Descrizione

Confirm that the subject is eligible to participate in the study and if not, that all the failed criteria have been marked.

Tipo di dati

text

Eligibility question
Descrizione

Eligibility question

Did the subject meet all the entry criteria?
Descrizione

If No, check all boxes corresponding to violations of any inclusion/exclusion criteria. Do not enter the subject into the study if they failed any inclusion or exclusion criteria below.

Tipo di dati

boolean

Inclusion criteria
Descrizione

Inclusion criteria

1. Men or non-pregnant/non-breast-feeding women of at least 30 years of age but no older than 70 at screening. Women of child-bearing potential must be practicing a clinically accepted method of contraception (such as oral contraception, surgical sterilization, intrauterine device [IUD], or diaphram IN ADDITION to spermicidal foam and condom on male partner, or systemic contraception [i.e. Norplantt System]), during the study and for at least one month prior to randomization and one month following completion of the study.
Descrizione

age and pregnancy

Tipo di dati

text

2. Diagnosis of idiopathic Parkinson's Disease (according to modified Hoehn & Yahr criteria Stages 1-111) and demonstrating lack of control with L-dopa therapy (e.g. mild wearing off, simple on/off fluctuations).
Descrizione

Diagnosis of idiopathic Parkinson's Disease

Tipo di dati

text

3. Subjects on 600 mg or less of L-dopa therapy for two years or less. Patients on combination therapy such as COMTAN/L-dopa or L-dopa and amantadine are also eligible.
Descrizione

L-dopa therapy

Tipo di dati

text

4. Subjects receiving a stable dose of L-dopa for at least four weeks prior to screening.
Descrizione

stable dose of L-dopa

Tipo di dati

text

5. Provide written informed consent for this study.
Descrizione

informed consent

Tipo di dati

text

6. Be willing and able to comply with study procedures, including follow-up clinic visits.
Descrizione

Compliance

Tipo di dati

text

Exclusion criteria
Descrizione

Exclusion criteria

1. Any stage of Parkinson's disease in which the subject demonstrates or has a history consistent with dyskinesia.
Descrizione

Dyskinesia

Tipo di dati

boolean

2. Presence, or history within the previous 3 months, of significant and/or uncontrolled psychiatric, hematological, renal, hepatic, endocrinological, neurological (other than Parkinson's Disease), or cardiovascular disease or active malignancy (other than basal cell cancer).
Descrizione

Disease

Tipo di dati

boolean

3. Any abnormality, at Screening, that the investigator deems to be clinically relevant on history, physical examination and in diagnostic laboratory tests including ECG.
Descrizione

Abnormality

Tipo di dati

boolean

4. Recent history of severe dizziness or fainting due to postural hypotension on standing.
Descrizione

dizziness or fainting

Tipo di dati

boolean

5. Clinically relevant Dementia or a MMSE score of <26.
Descrizione

Dementia

Tipo di dati

boolean

6. Recent history or current evidence of alcohol or drug abuse at the time of enrollment.
Descrizione

alcohol or drug abuse

Tipo di dati

boolean

7. Use of monoamine oxidase (MAO) inhibitors within three weeks of the screening visit except for the selective MAO-B inhibitor, selegiline.
Descrizione

Use of MAO inhibitors

Tipo di dati

boolean

8. Definite or suspected personal or family history of clinically significant adverse reactions or hypersensitivity to ropinirole (or to drugs with a similar chemical structure} that would preclude longterm dosing with ropinirole CR.
Descrizione

adverse reactions to ropinirole

Tipo di dati

boolean

9. Withdrawal, introduction, or change in dose of hormone replacement therapy and/or any drug known to substantially inhibit CYP1A2 (e.g. ciprofloxacine, fluvoxamine, cimetidine, ethinyloestradiol} or induce CYP1A2 (e.g. tobacco, omeprazole) within 7 days prior to enrollment. Subjects already on chronic therapy with any of these agents may be enrolled but must remain on stable doses of the agent from 7 days prior to enrollment through the end of the Treatment Period.
Descrizione

hormone replacement therapy

Tipo di dati

boolean

10. Use of an investigational drug within 30 days or 5 half-lives (which ever is longer).
Descrizione

Use of an investigational drug

Tipo di dati

boolean

Ritorna all'inizio della pagina

Similar models

Inclusion/exclusion GSK study Dyskinesia in Parkinson's disease NCT00363727

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
General information
Protocol identifier
Item
Protocol identifier
text
Subject Identifier
Item
Subject Identifier
text
C2348585 (UMLS CUI [1])
Visit Description
Item
Visit Description
text
Item Group
Inclusion and exclusion criteria
Monitor data validation check
Item
Monitor data validation check
text
Item Group
Eligibility question
Eligibility question
Item
Did the subject meet all the entry criteria?
boolean
Item Group
Inclusion criteria
Item
1. Men or non-pregnant/non-breast-feeding women of at least 30 years of age but no older than 70 at screening. Women of child-bearing potential must be practicing a clinically accepted method of contraception (such as oral contraception, surgical sterilization, intrauterine device [IUD], or diaphram IN ADDITION to spermicidal foam and condom on male partner, or systemic contraception [i.e. Norplantt System]), during the study and for at least one month prior to randomization and one month following completion of the study.
text
undefined item
Code List
1. Men or non-pregnant/non-breast-feeding women of at least 30 years of age but no older than 70 at screening. Women of child-bearing potential must be practicing a clinically accepted method of contraception (such as oral contraception, surgical sterilization, intrauterine device [IUD], or diaphram IN ADDITION to spermicidal foam and condom on male partner, or systemic contraception [i.e. Norplantt System]), during the study and for at least one month prior to randomization and one month following completion of the study.
CL Item
failed (failed)
CL Item
fulfilled (fulfilled)
Item
2. Diagnosis of idiopathic Parkinson's Disease (according to modified Hoehn & Yahr criteria Stages 1-111) and demonstrating lack of control with L-dopa therapy (e.g. mild wearing off, simple on/off fluctuations).
text
Diagnosis of idiopathic Parkinson's Disease
Code List
2. Diagnosis of idiopathic Parkinson's Disease (according to modified Hoehn & Yahr criteria Stages 1-111) and demonstrating lack of control with L-dopa therapy (e.g. mild wearing off, simple on/off fluctuations).
CL Item
failed (failed)
CL Item
fulfilled (fulfilled)
Item
3. Subjects on 600 mg or less of L-dopa therapy for two years or less. Patients on combination therapy such as COMTAN/L-dopa or L-dopa and amantadine are also eligible.
text
L-dopa therapy
Code List
3. Subjects on 600 mg or less of L-dopa therapy for two years or less. Patients on combination therapy such as COMTAN/L-dopa or L-dopa and amantadine are also eligible.
CL Item
failed (failed)
CL Item
fulfilled (fulfilled)
Item
4. Subjects receiving a stable dose of L-dopa for at least four weeks prior to screening.
text
stable dose of L-dopaprior to screening
Code List
4. Subjects receiving a stable dose of L-dopa for at least four weeks prior to screening.
CL Item
failed (failed)
CL Item
fulfilled (fulfilled)
Item
5. Provide written informed consent for this study.
text
informed consent
Code List
5. Provide written informed consent for this study.
CL Item
failed (failed)
CL Item
fulfilled (fulfilled)
Item
6. Be willing and able to comply with study procedures, including follow-up clinic visits.
text
Compliance
Code List
6. Be willing and able to comply with study procedures, including follow-up clinic visits.
CL Item
failed (failed)
CL Item
fulfilled (fulfilled)
Item Group
Exclusion criteria
Dyskinesia
Item
1. Any stage of Parkinson's disease in which the subject demonstrates or has a history consistent with dyskinesia.
boolean
Disease
Item
2. Presence, or history within the previous 3 months, of significant and/or uncontrolled psychiatric, hematological, renal, hepatic, endocrinological, neurological (other than Parkinson's Disease), or cardiovascular disease or active malignancy (other than basal cell cancer).
boolean
Abnormality
Item
3. Any abnormality, at Screening, that the investigator deems to be clinically relevant on history, physical examination and in diagnostic laboratory tests including ECG.
boolean
dizziness or fainting
Item
4. Recent history of severe dizziness or fainting due to postural hypotension on standing.
boolean
Dementia
Item
5. Clinically relevant Dementia or a MMSE score of <26.
boolean
alcohol or drug abuse
Item
6. Recent history or current evidence of alcohol or drug abuse at the time of enrollment.
boolean
Use of MAO inhibitors
Item
7. Use of monoamine oxidase (MAO) inhibitors within three weeks of the screening visit except for the selective MAO-B inhibitor, selegiline.
boolean
adverse reactions to ropinirole
Item
8. Definite or suspected personal or family history of clinically significant adverse reactions or hypersensitivity to ropinirole (or to drugs with a similar chemical structure} that would preclude longterm dosing with ropinirole CR.
boolean
hormone replacement therapy
Item
9. Withdrawal, introduction, or change in dose of hormone replacement therapy and/or any drug known to substantially inhibit CYP1A2 (e.g. ciprofloxacine, fluvoxamine, cimetidine, ethinyloestradiol} or induce CYP1A2 (e.g. tobacco, omeprazole) within 7 days prior to enrollment. Subjects already on chronic therapy with any of these agents may be enrolled but must remain on stable doses of the agent from 7 days prior to enrollment through the end of the Treatment Period.
boolean
Use of an investigational drug
Item
10. Use of an investigational drug within 30 days or 5 half-lives (which ever is longer).
boolean
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial